Silverarc Capital Management LLC Takes Position in uniQure (NASDAQ:QURE)

Silverarc Capital Management LLC bought a new position in uniQure (NASDAQ:QURE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 100,000 shares of the biotechnology company's stock, valued at approximately $1,766,000. Silverarc Capital Management LLC owned 0.21% of uniQure at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of QURE. Avoro Capital Advisors LLC bought a new stake in uniQure during the 4th quarter valued at approximately $38,410,000. Jump Financial LLC lifted its holdings in shares of uniQure by 193.5% during the fourth quarter. Jump Financial LLC now owns 211,776 shares of the biotechnology company's stock worth $3,740,000 after buying an additional 139,624 shares during the last quarter. Walleye Capital LLC boosted its position in shares of uniQure by 44.7% in the fourth quarter. Walleye Capital LLC now owns 130,423 shares of the biotechnology company's stock valued at $2,303,000 after acquiring an additional 40,281 shares during the period. XTX Topco Ltd bought a new stake in shares of uniQure in the fourth quarter valued at approximately $287,000. Finally, Quinn Opportunity Partners LLC grew its stake in shares of uniQure by 187.5% in the fourth quarter. Quinn Opportunity Partners LLC now owns 69,000 shares of the biotechnology company's stock worth $1,219,000 after acquiring an additional 45,000 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

uniQure Price Performance

Shares of uniQure stock traded down $0.08 during mid-day trading on Friday, reaching $14.18. 646,241 shares of the stock were exchanged, compared to its average volume of 1,772,228. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The company has a market cap of $766.81 million, a price-to-earnings ratio of -2.86 and a beta of 0.42. The firm has a 50-day simple moving average of $11.94 and a 200 day simple moving average of $11.54. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

Wall Street Analyst Weigh In

A number of analysts have weighed in on QURE shares. Royal Bank of Canada reissued an "outperform" rating and issued a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of uniQure in a research report on Monday. Chardan Capital initiated coverage on uniQure in a report on Tuesday, April 1st. They issued a "buy" rating and a $38.00 price target for the company. Wells Fargo & Company decreased their price objective on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Finally, StockNews.com upgraded uniQure to a "sell" rating in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, uniQure presently has an average rating of "Moderate Buy" and a consensus price target of $38.80.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 6,717 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the sale, the chief executive officer now owns 580,795 shares in the company, valued at approximately $6,574,599.40. This represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christian Klemt sold 2,916 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares of the company's stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is currently owned by insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.